Report #2847991

Received Jul 1, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	UNK	—

Symptoms (2)

Injection site erythemaInjection site swelling

Symptom narrative

Injection site swelling; Injection site erythema; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site swelling in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site swelling (Verbatim: Injection site swelling) and injection site erythema (Verbatim: Injection site erythema). The outcome of the injection site swelling and injection site erythema were not reported. It was unknown if the reporter considered the injection site swelling and injection site erythema to be related to Shingrix. It was unknown if the company considered the injection site swelling and injection site erythema to be related to Shingrix. Additional Information: GSK Receipt Date: 22-JUN-2025 This case was reported by a patient via interactive digital media. The reporter reported that after 1st dose of Shingrix the patient had redness and swelling at injection site.